Circio Holding ASA · OSL:CRNA
Circio Holding ASA — Targovax — Investor Day (2021)
13 slides from Circio Holding ASA's investor day presentation, 2021
Slide 1: ONCOS-102 development program
ONCOS-102 development program 4. Immune activation 5. Preclinical pipeline update 6. 4Q update 7. Closing remarks
Slide 2: Early-stage development successfully completed – entering late-stage development
EARLY-STAGE DEVELOPMENT SUCCESSFULLY COMPLETED – ENTERING LATE-STAGE DEVELOPMENT Expansion opportunities Late-stage development Mesothelioma Colorectal cancer Early-stage development PD1 refractory melanoma Other indications Other IO combinations Clinical efficacy Platform development Immune activat
Slide 3: Checkpoint inhibitors in the clinic
CHECKPOINT INHIBITORS IN THE CLINIC Huge impact since the launch of Yervoy in 2011 o aPD1 standard of care in several solid tumor indications o Varying response rates − Melanoma ca. 40% ORR − Lung ca. 30% ORR − Head & Neck ca. 20% ORR CPI refractory cancer is a significant medical need o Primary ref
Slide 4: PD1 refractory melanoma market opportunity
PD1 REFRACTORY MELANOMA MARKET OPPORTUNITY ~100.000 new stage III/IV cases of malignant Incidence melanoma per year in the major markets ~50% recur and become unresectable Unresectable Total ~50.000 patients per year ~50% of cases become PD resistant PD1 resistance Total ~25.000 patients per year Es
Slide 5: Accelerated approval in anti-PD1 refractory melanoma is our priority
ACCELERATED APPROVAL IN ANTI-PD1 REFRACTORY MELANOMA IS OUR PRIORITY Rationale Preliminary trial design – Next steps registration directed • Highly • Conclude trial design discussions competitive • Single arm, < 200 patients with KOLs in US, EU and Australia clinical data • Refractory status • Consu
Slide 6: Product candidate pipeline
Product candidate Preclinical Phase 1 Phase 2 Collaborator Melanoma Combination w/Keytruda Colorectal cancer ONCOS-102 Combination w/Imfinzi Mesothelioma Combination w/pemetrexed/cisplatin ONCOS-200 series Next Gen viruses Novel mutRAS concepts 45
Slide 7: Collaboration in colorectal cancer with Phase 1/2 trial combining ONCOS-102 and Imfinzi
COLLABORATION IN COLORECTAL CANCER WITH PHASE 1/2 TRIAL COMBINING ONCOS-102 AND IMFINZI Patients Primary colorectal cancer with peritoneal metastases Failed prior standard-of-care platinum chemotherapy Dose escalation Expansion Safety lead-in Simon’s two- Part 1 stage design Part 2 ONCOS-102 13 pati
Slide 8: Product candidate pipeline
Product candidate Preclinical Phase 1 Phase 2 Collaborator Melanoma Combination w/Keytruda Colorectal cancer Combination w/Imfinzi Mesothelioma ONCOS-102 Combination w/pemetrexed/cisplatin ONCOS-200 series Next Gen viruses Novel mutRAS concepts 47
Slide 9: Advanced malignant pleural mesothelioma Phase 1/2 trial in combination with chemo
ADVANCED MALIGNANT PLEURAL MESOTHELIOMA PHASE 1/2 TRIAL IN COMBINATION WITH CHEMO Experimental group n=14 Trial design ONCOS-102 plus 1st and 2nd line Safety lead-in SoC Chemo n=6 Randomized Standard of Care (SoC) pemetrexed/cisplatin +/- ONCOS-102 ONCOS-102 plus SoC Chemo Control group n=11 SoC Che
Slide 10: Clinical outcomes in 1st line compare favorably to historical control
CLINICAL OUTCOMES IN 1ST LINE COMPARE FAVORABLY TO HISTORICAL CONTROL ONCOS-102 +Pem/cis mPFS Pem/cis (or carbo) months Checkpoint trials 11 Targovax experimental8 10 Min. 9 8 Targovax control8 Min. Max. Zalcman5 7 Nowak7 Ceresoli3 Baas5 chemo/durva Scagliotti4 control Ipi/Nivo 6 Vogelzang2 just app
Slide 11: Fast Track designation and evolving survival data provide opportunities
FAST TRACK DESIGNATION AND EVOLVING SURVIVAL DATA PROVIDE OPPORTUNITIES Well tolerated combination therapy Clear clinical activity in 1st line patients Interim survival data promising even without CPI FDA granted Fast Track designation in mesothelioma Next steps Continue follow patients to determine
Slide 12: ONCOS-102 opportunities beyond melanoma and mesothelioma
ONCOS-102 OPPORTUNITIES BEYOND MELANOMA AND MESOTHELIOMA COLORECTAL o Large medical need and strong scientific o Data expected during 1H 2022 rationale for CPI combination o Review opportunity and o Met predetermined efficacy threshold in development with AstraZeneca Simon two-stage trial FURTHER OP
Slide 13: Clinical and preclinical pipeline
CLINICAL AND PRECLINICAL PIPELINE Product candidate Preclinical Phase 1 Phase 2 Collaborator Next expected event Melanoma 1H 2022 Combination w/anti PD1 First patient Colorectal cancer Update by collaborator – ONCOS-102 Combination w/Imfinzi clinical data expected 1H22 Mesothelioma 1H 2021 Combinati